|
|
| | Ergoline-8-carboxamide, N-[3-[di(methyl-d3)amino]propyl]-N-[(ethylamino)carbonyl]-6-(2-propen-1-yl)-, (8β)- Basic information |
| | Ergoline-8-carboxamide, N-[3-[di(methyl-d3)amino]propyl]-N-[(ethylamino)carbonyl]-6-(2-propen-1-yl)-, (8β)- Chemical Properties |
| density | 1.157±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | solubility | Acetonitrile: Soluble DMSO: Soluble |
| | Ergoline-8-carboxamide, N-[3-[di(methyl-d3)amino]propyl]-N-[(ethylamino)carbonyl]-6-(2-propen-1-yl)-, (8β)- Usage And Synthesis |
| Uses | Cabergoline-d6 is deuterium labeled Cabergoline. Cabergoline is an ergot derived-dopamine D2-like receptor agonist that has high affinity for D2, D3, and 5-HT2B receptors (Ki=0.7, 1.5, and 1.2, respectively). | | IC 50 | D3 Receptor; D2 Receptor | | References | [1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:10.1177/1060028018797110 [2] Odaka H, et al. Cabergoline, dopamine D2 receptor agonist, prevents neuronal cell death under oxidative stress via reducing excitotoxicity. PLoS One. 2014 Jun 10;9(6):e99271. DOI:10.1371/journal.pone.0099271 [3] Jefferson F, et al. A dopamine receptor d2-type agonist attenuates the ability of stress to alter sleep in mice. Endocrinology. 2014 Nov;155(11):4411-21. DOI:10.1210/en.2014-1134 [4] M MIYAGI. Dopamine receptor affinities in vitro and stereotypic activities in vivo of cabergoline in rats.[J]. Biological & pharmaceutical bulletin, 1996, 19 9: 1210-1213. DOI: 10.1248/bpb.19.1210 [5] K EGUCHI. Effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors: in vitro culture studies.[J]. Endocrine journal, 1995, 42 3: 413-420. DOI: 10.1507/endocrj.42.413 [6] SHAO JIAN LIN. Suppression of mTOR pathway and induction of autophagy-dependent cell death by cabergoline.[J]. Oncotarget, 2015, 6 36: 39329-39341. DOI: 10.18632/oncotarget.5744 [7] R. GRONDIN . Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates[J]. Brain Research, 1996, 735 2: Pages 298-306. DOI: 10.1016/0006-8993(96)00597-5 |
| | Ergoline-8-carboxamide, N-[3-[di(methyl-d3)amino]propyl]-N-[(ethylamino)carbonyl]-6-(2-propen-1-yl)-, (8β)- Preparation Products And Raw materials |
|